CVSA
Covista Inc.
CVSA has the edge over EBAY overall, supported by stronger valuation and stronger modeled upside.
EBAY
eBay Inc.
EBAY has slightly lower modeled downside risk, despite its lower overall score.
CVSA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
CVSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
EBAY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
EBAY's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
CVSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $44.17 | -63% |
| Forward | 13x | $119 | — |
| Current | 16x | $119 | — |
| Fair | 18x | $135 | +14% |
| Expensive | 24x | $173 | +46% |
Historical ranges are pointers, not guarantees.
CVSA has the edge over EBAY in the historical PE scenario, which offers more potential upside but is not a forecast.
EBAY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.9x | $31.50 | -74% |
| Fair | 16x | $71.96 | -40% |
| Forward | 18x | $120 | — |
| Expensive | 22x | $99.04 | -18% |
| Current | 26x | $120 | — |
Historical ranges are pointers, not guarantees.
EBAY's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 18x next year's earnings.
CVSA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
CVSA has the edge over EBAY on the outlook, with more favorable profitability expectations.
EBAY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for EBAY, with profitability holding steady.
CVSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.18 | +25% |
| Q3 2026 | $7.32 | +9.7% |
| Q2 2026 | $7.04 | +14% |
| Q1 2026 | $6.41 | +7.2% |
| Q4 2025 | $6.80 | +28% |
| Q3 2025 | $6.67 | +54% |
| Q2 2025 | $6.18 | +82% |
| Q1 2025 | $5.98 | +127% |
| Q4 2024 | $5.32 | +96% |
CVSA has the edge over EBAY on earnings, with more consistent year-over-year improvement.
EBAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.63 | +45% |
| Q3 2026 | $4.57 | +0.4% |
| Q2 2026 | $4.82 | +7.3% |
| Q1 2026 | $4.40 | +6% |
| Q4 2025 | $4.34 | +10% |
| Q3 2025 | $4.55 | +15% |
| Q2 2025 | $4.49 | -12% |
| Q1 2025 | $4.15 | -17% |
| Q4 2024 | $3.94 | -24% |
EBAY's earnings per share have fallen from their peak: $4.57 over the past year, against $20.25 in late 2021.
CVSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $511.5M | +11% |
| Q2 2026 | $501.4M | +9.7% |
| Q1 2026 | $487M | +4.5% |
| Q4 2025 | $503.4M | +12% |
| Q3 2025 | $462.3M | +11% |
| Q2 2025 | $457.1M | +12% |
| Q1 2025 | $466.1M | +13% |
| Q4 2024 | $447.7M | +14% |
CVSA's revenue has grown year over year for 15 quarters in a row: $512M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.7 points |
| Q2 2026 | 19% | +2.2 points |
| Q1 2026 | 19% | -0.7 points |
| Q4 2025 | 22% | -1.1 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 17% | +0.1 points |
| Q1 2025 | 19% | +4.5 points |
| Q4 2024 | 23% | +8.3 points |
CVSA's operating margin was 19% last quarter, up 0.7 points from the same quarter a year ago.
EBAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.2B | +14% |
| Q2 2026 | $3.1B | +15% |
| Q1 2026 | $3.1B | +19% |
| Q4 2025 | $3B | +15% |
| Q3 2025 | $2.8B | +9.5% |
| Q2 2025 | $2.7B | +6.1% |
| Q1 2025 | $2.6B | +1.1% |
| Q4 2024 | $2.6B | +0.7% |
EBAY has the edge over CVSA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -1.2 points |
| Q2 2026 | 22% | +3.8 points |
| Q1 2026 | 20% | -4 points |
| Q4 2025 | 20% | -0.8 points |
| Q3 2025 | 20% | -2.7 points |
| Q2 2025 | 18% | -3.6 points |
| Q1 2025 | 24% | -0.9 points |
| Q4 2024 | 21% | +5.1 points |
EBAY has the edge over CVSA on profitability, with a higher operating margin.
CVSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $76.4M | -33% |
| Q2 2026 | $97.1M | +139% |
| Q1 2026 | $165.9M | -16% |
| Q4 2025 | $15.1M | +$44.8M |
| Q3 2025 | $114.5M | +45% |
| Q2 2025 | $40.7M | -6.8% |
| Q1 2025 | $197.7M | +40% |
| Q4 2024 | -$29.7M | -$7.3M |
CVSA generated $355M in free cash flow over the past year, up 9.7% from the year before.
EBAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $749M | -6.7% |
| Q2 2026 | $300M | +$741M |
| Q1 2026 | $897M | +39% |
| Q4 2025 | $466M | -17% |
| Q3 2025 | $803M | +24% |
| Q2 2025 | -$441M | -259% |
| Q1 2025 | $644M | +36% |
| Q4 2024 | $560M | +$564M |
EBAY has the edge over CVSA on cash flow, with more consistent year-over-year improvement.
CVSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.2x | Healthy |
CVSA has the edge over EBAY on leverage, with a lower net debt burden relative to earnings.
EBAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.9x | Healthy |
EBAY's net debt is about 1.9 years of its operating earnings (EBITDA), up from 1.7 years a year ago.
CVSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 24.4 | Neutral |
CVSA's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).
EBAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.9 | Neutral |
| Stochastic | 80.0 | Overbought |
EBAY's weekly RSI is 62 (neutral) and its Stochastic is 80 (overbought).
CVSA PE vs Consumer Cyclical Sector
| Metric | CVSA | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 9.8% below |
| PE % | 33 | 47 | 14 pts below |
CVSA has the edge over EBAY on valuation relative to its sector.
EBAY PE vs Consumer Cyclical Sector
| Metric | EBAY | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 18x | 46% above |
| PE % | 91 | 47 | 44 pts above |
EBAY is trading at 26x earnings, a 46% premium to the Consumer Cyclical sector's median of 18x.
CVSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $123.5 | 3.6% below |
| 20 week MA | $126.4 | 5.8% below |
| 50 week MA | $117.5 | 1.3% above |
| 100 week MA | $116.5 | 2.2% above |
| 200 week MA | $85.9 | 39% above |
CVSA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 39% above its 200-week average.
EBAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.5 | 3.1% above |
| 20 week MA | $112.4 | 6.9% above |
| 50 week MA | $102.6 | 17% above |
| 100 week MA | $89.8 | 34% above |
| 200 week MA | $69.5 | 73% above |
EBAY has the edge over CVSA on trend strength, trading above more of its moving averages.
CVSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.0 | $34.4 | -1.8% |
| 2021 | $34.4 | $30.0 | -13% |
| 2022 | $30.0 | $36.2 | +20% |
| 2023 | $36.2 | $59.0 | +63% |
| 2024 | $59.0 | $90.9 | +54% |
| 2025 | $90.9 | $104.7 | +15% |
| 2026 YTD | $104.7 | $119.0 | +14% |
CVSA has finished higher in four of the last six years, two of them by more than 50%. It's up 14% so far in 2026.
EBAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.1 | $50.1 | +39% |
| 2021 | $50.1 | $64.9 | +29% |
| 2022 | $64.9 | $40.2 | -38% |
| 2023 | $40.2 | $43.6 | +8.6% |
| 2024 | $43.6 | $62.8 | +44% |
| 2025 | $62.8 | $85.2 | +36% |
| 2026 YTD | $85.2 | $120.1 | +41% |
EBAY has the edge over CVSA on returns for 2026, with the stronger performance.